Announcements

  • All
  • Announcements 2009
  • Announcements 2010
  • Announcements 2011
  • Announcements 2012
  • Announcements 2017
  • Announcements 2018
  • Announcements 2019
  • Announcements 2020
  • Announcements 2021
  • Announcements 2022
  • Announcements 2024

 Peania, November 29th 2019 - Lavipharm S.A., pursuant to Article 19 of the European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that, T & A Holdings (Luxembourg) Sarl, a company related to Lavipharm S.A.'s Executive Chairman, Mr. Athanasios...

Peania, November 13th2019 Η Lavipharm S.A. announces that as of today, November 13th 2019, Mr. Panagiotis Giannouleas, an experienced executive in the pharmaceutical market, assumes the responsibilities of Chief Operating Officer (COO) and Country Manager. ...

Lavipharm S.A. announces that, as of September 6th  2019, Mr. Antonis Vogiatzis, who held the position of General Manager, is no longer with the company....

  Peania, December 6th 2018 - Lavipharm S.A., pursuant to Article 19 of the European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that, on December 3rd, 2018, T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's...

  Peania, October 24th 2018 - Lavipharm S.A., pursuant to Article 19 of the European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's Executive Chairman, Mr. Athanasios...

  Peania, June 29th 2018 - Lavipharm S.A., pursuant to Article 19 of European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that on 28.06.2018, T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's Executive Chairman, Mr....

  Peania, February 9th, 2018 - Lavipharm S.A., pursuant to Article 19 of European Parliament Regulation No 596/2014 and its Board dated 16/04/2014, hereby informs the investment community that on 07.02.2018, T & A Holdings (Luxembourg) sarl, a company related to Lavipharm SA's Executive Chairman, Mr....

  Peania, September 29th, 2017 – In the First Half of 2017, Lavipharm reports increased Consolidated Turnover mainly attributed to international sales, despite economic pressures, sustained regulatory constraints and decrease of the pharmaceutical market in Greece. At the same time, the sharp drop in loans and...

  Recession and instability features were evident in the Greek economy during 9M 2012, while in Healthcare, variability and constant changes influenced the whole sector. Within this negative business environment, Lavipharm focused on enhancing its export activity and strengthening its competitiveness, through the further decrease of...

  During H1 2012, in an environment characterized by a political instability and recession rates, Lavipharm focused on enhancing its export activities, sustaining its market shares and strengthening its competitiveness while reducing operational costs and increasing productivity. In H1 2012, consolidated financial results were significantly affected by...